Glenmede Trust’s Halozyme HALO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $11.1M | Sell |
141,317
-5,400
| -4% | -$368K | 0.05% | 332 |
|
|
2026
Q1 | $9.48M | Buy |
146,717
+26,851
| +22% | +$1.89M | 0.05% | 344 |
|
|
2025
Q4 | $8.07M | Buy |
+119,866
| New | +$8.06M | 0.04% | 382 |
|
|
2025
Q1 | $31.8M | Buy |
499,029
+15,077
| +3% | +$876K | 0.17% | 120 |
|
|
2024
Q4 | $23.1M | Sell |
483,952
-3,179
| -0.7% | -$163K | 0.12% | 158 |
|
|
2024
Q3 | $27.9M | Buy |
487,131
+109,283
| +29% | +$6.27M | 0.13% | 151 |
|
|
2024
Q2 | $19.8M | Buy |
377,848
+5,682
| +2% | +$249K | 0.1% | 201 |
|
|
2024
Q1 | $15.1M | Buy |
372,166
+37,447
| +11% | +$1.4M | 0.08% | 278 |
|
|
2023
Q4 | $12.4M | Sell |
334,719
-8,469
| -2% | -$319K | 0.06% | 317 |
|
|
2023
Q3 | $13.1M | Sell |
343,188
-3,268
| -0.9% | -$134K | 0.07% | 277 |
|
|
2023
Q2 | $13.2M | Buy |
346,456
+659
| +0.2% | +$22.5K | 0.07% | 273 |
|
|
2023
Q1 | $13.2M | Buy |
345,797
+3,597
| +1% | +$169K | 0.07% | 270 |
|
|
2022
Q4 | $19.5M | Sell |
342,200
-42,399
| -11% | -$2.17M | 0.11% | 197 |
|
|
2022
Q3 | $15.2M | Sell |
384,599
-46,586
| -11% | -$2.06M | 0.1% | 233 |
|
|
2022
Q2 | $19M | Sell |
431,185
-47,243
| -10% | -$2.04M | 0.11% | 205 |
|
|
2022
Q1 | $19.1M | Buy |
+478,428
| New | +$17M | 0.09% | 255 |
|
|
2020
Q4 | – | Sell |
-241
| Closed | -$6K | – | 1652 |
|
|
2020
Q3 | $6K | Buy |
241
+92
| +62% | +$2.56K | ﹤0.01% | 2042 |
|
|
2020
Q2 | $3K | Buy |
+149
| New | +$3.36K | ﹤0.01% | 2177 |
|
|
2019
Q4 | – | Sell |
-200
| Closed | -$3K | – | 3062 |
|
|
2019
Q3 | $3K | Hold |
200
| – | – | ﹤0.01% | 2765 |
|
|
2019
Q2 | $3K | Hold |
200
| – | – | ﹤0.01% | 2756 |
|
|
2019
Q1 | $3K | Hold |
200
| – | – | ﹤0.01% | 2740 |
|
|
2018
Q4 | $2K | Buy |
+200
| New | +$3.19K | ﹤0.01% | 2762 |
|
|
2018
Q2 | – | Sell |
-635
| Closed | -$12K | – | 2075 |
|
|
2018
Q1 | $12K | Hold |
635
| – | – | ﹤0.01% | 2125 |
|
|
2017
Q4 | $12K | Buy |
+635
| New | +$11.7K | ﹤0.01% | 2125 |
|
|
2016
Q3 | – | Sell |
-173
| Closed | -$1K | – | 2624 |
|
|
2016
Q2 | $1K | Hold |
173
| – | – | ﹤0.01% | 2463 |
|
|
2016
Q1 | $1K | Buy |
+173
| New | +$1.63K | ﹤0.01% | 2500 |
|
|
2014
Q3 | – | Sell |
-543
| Closed | -$5K | – | 2479 |
|
|
2014
Q2 | $5K | Sell |
543
-200
| -27% | -$1.7K | ﹤0.01% | 2153 |
|
|
2014
Q1 | $9K | Buy |
743
+200
| +37% | +$2.97K | ﹤0.01% | 2059 |
|
|
2013
Q4 | $8K | Buy |
+543
| New | +$6.98K | ﹤0.01% | 2037 |
|
Other funds holding HALO
Glenmede Trust's HALO Position: Q2 2026 in Review
Glenmede Trust reduced its Halozyme (HALO) stake by 3.7% in Q2 2026, selling an estimated $368K and leaving 141,317 shares worth $11.1M. The position accounts for 0.05% of the portfolio, ranked #332.
Glenmede Trust first reported a position in HALO in Q4 2013 and has held it in 29 quarters since. The position peaked at $31.8M in Q1 2025. 671 funds tracked by Wall St. Rank hold HALO as of Q2 2026.
- Glenmede Trust held 141,317 shares of Halozyme worth $11.1M as of Q2 2026.
- Glenmede Trust sold 5,400 Halozyme shares in Q2 2026, an estimated $368K.
- Halozyme made up 0.05% of Glenmede Trust's portfolio in Q2 2026, its #332 holding.
- Glenmede Trust first reported a position in Halozyme in Q4 2013 and has held it in 29 quarters since.
- Glenmede Trust's Halozyme position peaked at $31.8M in Q1 2025.
- 671 funds tracked by Wall St. Rank held Halozyme as of Q2 2026.
Based on Glenmede Trust's 13F filing for Q2 2026, filed 10 Aug 2026.